Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Suspended 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Genitourinary 3Dermatologic 3Breast 3Gynecologic 2Gastrointestinal 2Other solid neoplasm 1Head & Neck 1

Conditions

Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Neoplasms 6Lymphoma, Non-Hodgkin 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neoplasm Metastasis 3Multiple Myeloma 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Small Cell Lung Carcinoma 2Skin Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2

Interventions

pembrolizumab 75Carboplatin 46Paclitaxel 44130-nm albumin-bound paclitaxel 35Gemcitabine 34Cyclophosphamide 23Capecitabine 22Nivolumab 21Albumin-Bound Paclitaxel 21atezolizumab 20sacituzumab govitecan 14spartalizumab 13Doxorubicin 11olaparib 9Cisplatin 9Bevacizumab 9eribulin 8fludarabine 7durvalumab 7avelumab 7Injections 7Fulvestrant 7Fluorouracil 7Vinorelbine 6Leucovorin 6Docetaxel 6iniparib 5budigalimab 5Ipilimumab 5Epirubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Breast Neoplasms × Interleukin-2 × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
12 enrolled
BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

PACT Pharma, Inc.

Phase 1 Suspended
21 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡